Literature DB >> 16905585

High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment.

G M Bartelds, G J Wolbink, S Stapel, L Aarden, W F Lems, B A C Dijkmans, M T Nurmohamed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16905585      PMCID： PMC1798278          DOI： 10.1136/ard.2005.049858

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

Review 1.  New drugs for rheumatoid arthritis.

Authors:  Nancy J Olsen; C Michael Stein
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

2.  Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.

Authors:  J Pijpe; G W van Imhoff; F K L Spijkervet; J L N Roodenburg; G J Wolbink; K Mansour; A Vissink; C G M Kallenberg; H Bootsma
Journal:  Arthritis Rheum       Date:  2005-09

3.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.

Authors:  Gerrit Jan Wolbink; Marijn Vis; Willem Lems; Alexandre E Voskuyl; Els de Groot; Michael T Nurmohamed; Steven Stapel; Paul P Tak; Lucien Aarden; Ben Dijkmans
Journal:  Arthritis Rheum       Date:  2006-03

4.  Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.

Authors:  G J Wolbink; A E Voskuyl; W F Lems; E de Groot; M T Nurmohamed; P P Tak; B A C Dijkmans; L Aarden
Journal:  Ann Rheum Dis       Date:  2004-10-14       Impact factor: 19.103

5.  Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.

Authors:  A M van Gestel; C J Haagsma; P L van Riel
Journal:  Arthritis Rheum       Date:  1998-10
  5 in total
  10 in total

Review 1.  The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.

Authors:  W W Cheng; T M Allen
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

Review 2.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

3.  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.

Authors:  Fiona A Harding; Marcia M Stickler; Jennifer Razo; Robert B DuBridge
Journal:  MAbs       Date:  2010-05-01       Impact factor: 5.857

4.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

Authors:  Geertje M Bartelds; Carla A Wijbrandts; Michael T Nurmohamed; Steven Stapel; Willem F Lems; Lucien Aarden; Ben A C Dijkmans; Paul Peter Tak; Gerrit Jan Wolbink
Journal:  Ann Rheum Dis       Date:  2007-02-14       Impact factor: 19.103

5.  Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases.

Authors:  Kunihiro Ichinose; Tomoki Origuchi; Shin-ya Kawashiri; Naoki Iwamoto; Keita Fujikawa; Toshiyuki Aramaki; Makoto Kamachi; Kazuhiko Arima; Mami Tamai; Hideki Nakamura; Hiroaki Ida; Atsushi Kawakami; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2011-01-18       Impact factor: 2.631

Review 6.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Authors:  Joachim R Kalden; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

7.  Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy.

Authors:  Xiaoyi Zhu; Fei Yu; Yanling Wu; Tianlei Ying
Journal:  Antib Ther       Date:  2021-05-17

Review 8.  Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.

Authors:  Sebastian P Fuchs; Ronald C Desrosiers
Journal:  Mol Ther Methods Clin Dev       Date:  2016-11-16       Impact factor: 6.698

9.  Identification of HLA-DRB1 association to adalimumab immunogenicity.

Authors:  Mohan Liu; Jacob Degner; Justin Wade Davis; Kenneth B Idler; Ahmed Nader; Nael M Mostafa; Jeffrey F Waring
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

Review 10.  Engineering Antibodies for the Treatment of Infectious Diseases.

Authors:  Gaowei Fan; Jinming Li
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.